GlassScriptPhysician profile
Mohammad Al-Ali
NPI 1629275789
$5,168.59
in general payments reported to CMS, 2019-2025
33 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $448 · 2021: $1,241 · 2022: $719 · 2023: $681 · 2024: $750 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.65 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $974.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $620.87 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $487.83 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $361.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.14 | 2019-2025 | Ofev, Stiolto Respimat |
| Insmed, INC. | $231.34 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $220.44 | 2020-2025 | Wakix |
| Actelion Pharmaceuticals US, INC. | $207.32 | 2019-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $200.52 | 2019-2025 | |
| Mylan Specialty L.P. | $157.83 | 2020-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $131.66 | 2019-2025 | Dupixent |
| Resmed Corp | $107.09 | 2019-2025 | |
| Genentech USA, INC. | $97.53 | 2019-2022 | |
| Amgen INC. | $97.20 | 2022-2025 | Tavneos, Tezspire |
| Novartis Pharmaceuticals Corporation | $93.17 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $89.85 | 2019-2025 | |
| Axsome Therapeutics, INC. | $87.45 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $86.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.51 | 2020-2022 | |
| Csl Behring | $73.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $65.48 | 2019-2020 | |
| Abbvie INC. | $61.12 | 2022-2025 | Avycaz |
| Gilead Sciences, INC. | $54.60 | 2022-2024 | Veklury |
| Circassia INC. | $37.88 | 2019 | |
| Grifols USA, LLC | $37.59 | 2021-2023 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $34.19 | 2019 | |
| Baxter Healthcare | $33.84 | 2023 | Hillrom - Life 2000 Ventilation System |
| Allergan, INC. | $28.19 | 2019-2020 | |
| Medtronic, INC. | $25.65 | 2025 | Illumisite |
| Advanced Respiratory, INC | $22.93 | 2021 | |
| Verona Pharma, INC. | $21.45 | 2025 | Ohtuvayre |
| Smith+Nephew, INC. | $16.06 | 2019 | |
| Shire North American Group INC | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Al-Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.